Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold
With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis portfolio.
With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis portfolio.
What's Your Reaction?
